

\*\*\*\*\*

**Brakke Consulting's  
Animal Health News & Notes for June 3, 2016**  
*Copyright © Brakke Consulting, Inc.*

*Editor: Lynn Fondon DVM MBA*

\*\*\*\*\*

IN THE NEWS:

[Brakke Consulting news](#)  
[Transaction assistance](#)

other news

[Alivira Animal Health](#)

[Bayer](#)

[Biovac Laboratories](#)

[Ceva](#)

[CZ Veterinaria](#)

[Elanco](#)

[Embark Veterinary](#)

[Hill's](#)

[Karizoo Group](#)

[Laboratorios Leti](#)

[Med-Pharmex](#)

[Merck](#)

[Merial](#)

[Parnell](#)

[Piddle Place](#)

[Premier Vet Alliance](#)

[Radio Systems Corporation](#)

[Strategic Veterinary Pharmaceuticals](#)

[SynDaver](#)

[TransferTech Sherbrooke](#)

[Veterinary Products](#)

[Vetstream](#)

\*\*\*\*\*

**BRAKKE CONSULTING, INC.  
TRANSACTION ASSISTANCE**

Let Brakke Consulting provide assistance for all your transactions.

Brakke Consulting has been the finder of record, agent of record or consultant for a number of successfully completed projects. We assist with valuations and provide due diligence on confidential transactions as well as offering executive counsel on a number of potential transactions.

Brakke Consulting has the experience, insight, ability and contacts to provide clients with the highest quality services in the animal health, pet, veterinary and specialty chemicals markets. Please contact any of our offices for a confidential consultation.

[www.BrakkeConsulting.com](http://www.BrakkeConsulting.com)

\*\*\*\*\*

**COMPANY NEWS RELEASES**

> The FDA announced it has approved **Elanco's** Onsior (robenacoxib) tablets for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs. (*FDA*)

> **Parnell Pharmaceuticals Holdings** Ltd announced the commencement of a Contract Manufacturing Agreement with **Merial**. Under the terms of the Agreement, Merial will purchase certain sterile injectable products exclusively from Parnell, with minimum annual purchase commitments over the 10-year term of the agreement. Parnell estimates the total value of the agreement between \$7 million and \$20 million depending on volume of product purchased by Merial over the 10-year term. (*Streetinsider.com*)

> The FDA announced it has approved an Abbreviated New Animal Drug Application for **Med-Pharmex's** Mometavet (generic equivalent for Mometamax) topical suspension for the treatment of otitis externa in dogs. (*FDA*)

> **Strategic Veterinary Pharmaceuticals** announced it has received FDA approval for its Oxytocin Injection 20 USP units/ml, for 24-month expiry at controlled room temperature. (*Vet Advantage*)

> **Hill's Pet Nutrition** announced the launch of Hill's Prescription Diet Mobility Treats for dogs to support healthy mobility. (*company announcement*)

> **Alivira Animal Health** Limited announced a definitive agreement to acquire a 60% stake in **Karizoo Group**. Karizoo Group achieved net sales of EUR 29.1 million (\$32 million) in 2015 with an adjusted EBITDA of EUR 2.2 million (\$2.5 million). Karizoo has a strong presence across 14 countries including Spain, Poland, Germany, United Kingdom, Mexico and Iran. (*Business-standard.com*)

> **Embark Veterinary** Inc., in partnership with the Cornell University College of Veterinary Medicine, announced the launch of the Embark Dog DNA Test. The test tracks over 200,000 genetic markers, offering ancestry analysis as well as key insights into genetic disease risk and heritable traits. (*Benzinga.com*)

> **Radio Systems Corporation** announced it has acquired **Piddle Place**, a maker of indoor dog toilets and Bio-Enzyme Treatment, an eco-friendly concentrate that breaks down pet waste and eliminates stubborn pet odors. Financial terms were not disclosed. (*Pet Age*)

> Premier Veterinary Group subsidiary **Premier Vet Alliance** (US) Ltd has signed a major agreement with distributor co-op **Veterinary Products Inc** (VPI) to supply the Company's preventative healthcare program for pets, branded in the US as "Premier Pet Care Plan" (PPCP), to VPI's 600 member hospitals across 15 States, located primarily in the Southeastern US. (*Stockmarketwire.com*)

> **SynDaver** announced the launch of a canine surgery model made entirely of synthetic material. The model was created to provide veterinary students with anatomically correct bodies for surgical practice in place of using cadavers. SynDaver's models are created with functioning bodily systems, complete with a heartbeat, a circulatory system, lungs that inflate and flesh that bleeds when cut. (*ABCnews*)

> The World Small Animal Veterinary Association (WSAVA) has appointed veterinary digital services specialist **Vetstream** as a Global Educational Partner. Under the terms of the partnership, Vetstream will offer Vetlexicon Canis, Felis and Lapis to members of WSAVA member associations at preferential pricing. For 12 of the world's developing countries this will be free of charge. (*company press release*)

> FRANCE **Ceva Santé Animale** announced it has acquired **Biovac Laboratories**, a French firm specializing in autogenous vaccines, allergy treatments and reagents. Financial terms were not disclosed. (*Animal Pharm*)

> UK MSD Animal Health (**Merck**) announced it has signed an agreement with Spanish-based **CZ Veterinaria S.A.** to distribute its Bluevac BTV8 bluetongue vaccine in certain European countries. MSD Animal Health anticipates that supplies of Bluevac BTV8 will be available to selected European countries, including the UK, in mid-July. (*TheCattleSite.com*)

> CANADA **Bayer** and **TransferTech Sherbrooke**, the corporate entity responsible for commercializing the innovations emerging from the Université de Sherbrooke and its affiliated institutions, announced a global license agreement to advance a novel vaccine candidate discovered at the University to help protect dairy cattle from mastitis caused by the bacterium *Staphylococcus aureus*. Financial terms were not disclosed. (*Finchannel.com*)

> EU **Laboratorios Leti** announced that it has received EU approval for its vaccine for active immunization against canine parasitic leishmaniasis caused by the parasite *Leishmania infantum*. (*Animal Pharm*)

\*\*\*\*\*

### ANIMAL HEALTH NEWS

> SWITZERLAND - RHD Switzerland has been struck by its first outbreak of rabbit hemorrhagic disease RHDV-2. The outbreak took place in rabbit farms near Zurich and Valais with 32 rabbits killed and another 28 vulnerable to the disease. The area near the rabbits has been quarantined and premises disinfected. There has been no vaccination strategy employed. (*Animal Pharm*)

> UK - BOVINE TB RESEARCH A new blood test to detect Mycobacteria in blood has been developed by researchers at the University of Nottingham. This new, simple and inexpensive blood test detects very low levels of mycobacteria in blood using a bacteriophage-based technique. The test is currently licensed to a spin-out company, **PBD Biotech Ltd.** (*ScienceDaily.com*)

> WORLD - KETAMINE The United Nations Commission on Narcotic Drugs took no action to place ketamine under international control. China previously had proposed that the commission place ketamine under schedule I of the Convention on Psychotropic Substances, the most restrictive category. Ketamine currently is a schedule III drug in the US. (*AVMA*)

\*\*\*\*\*

### BRAKKE CONSULTING VIEWPOINT

This week's news is a mix of additional generic drug approvals, expanded label claims on current FDA approved products and marketing, research and manufacturing agreements. Our reading is that 2016 is moving along nicely for most companies with increases in revenues.

Weather conditions in most of the US appear to be favorable for grass and feed grain production. It is also favorable for the production of fleas, ticks, flies and other parasites. If this trend continues, this is likely to be another excellent year for animal health companies. I'm currently in the Midwest where the cattle are being worked and then put out to lush pastures for the summer. There should be plenty of either grass or corn-feed beef to harvest this fall.

Have a great weekend!

Ron Brakke

\*\*\*\*\*

Trouble viewing this newsletter? You can view it online at [www.BrakkeConsulting.com](http://www.BrakkeConsulting.com)

*This electronic newsletter is the sole property of Brakke Consulting, Inc.  
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.*

For more information about Brakke Consulting's services and syndicated studies, visit our website at [www.brakkeconsulting.com](http://www.brakkeconsulting.com).

Brakke Consulting, Inc.  
12005 Ford Rd., Suite 530  
Dallas, TX 75234 USA